Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

Key facts

Sponsor

Memorial Sloan Kettering Cancer Center

Principal Investigator

Ghassan Abou-Alfa, MD

Memorial Sloan Kettering Cancer Center

Intervention

everolimus(drug)

Enrollment

28 target

Eligibility

12 years · All sexes

Timeline

2012 – 2021

Study locations (6)

• University of California San Francisco, San Francisco, California, United States
• John Hopkins Medical Center, Baltimore, Maryland, United States
• Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
• Brigham and Women's Hospital, Boston, Massachusetts, United States
• Dana-Farber Cancer Institute, Boston, Massachusetts, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States

Collaborators

Fibrolamellar Cancer Foundation · Dana-Farber Cancer Institute · Johns Hopkins University · University of California, San Francisco · Abbott · Novartis Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06789198
  Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA
  University Hospital Tuebingen
• RECRUITINGPHASE1, PHASE2NCT06620302
  Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
  Children's Oncology Group
• RECRUITINGPHASE1, PHASE2NCT06027086
  DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• RECRUITINGPHASE1NCT05937295
  FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition
  University Hospital Tuebingen
• RECRUITINGPHASE1, PHASE2NCT05468359
  Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
  St. Jude Children's Research Hospital
• RECRUITINGPHASE1, PHASE2NCT04380545
  Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
  M.D. Anderson Cancer Center
• RECRUITINGPHASE2NCT04134559
  Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
  Allison O'Neill, MD

See all trials for Fibrolamellar hepatocellular carcinoma →